Updated Jul 16, 2026 · Last SEC filing 2026-07-10
Contineum Therapeutics, Inc. (CTNM) has filed 14 SEC Form 4 insider transactions in the last 90 days, with the most recent on 2026-07-10. 3 Form 8-K material event filings were reported by CTNM in the last 90 days. 7 Form 144 notices of proposed sale were filed for CTNM stock. InsiderAlpha tracks every CTNM SEC filing — Form 4, Form 144, and 8-K — in real time, including Rule 10b5-1 plan detection.
| SEC CIK | 0001855175 |
|---|
| Form 4 filings (90d) | 14 |
|---|---|
| Form 8-K filings (90d) | 3 |
| Form 144 notices (90d) | 7 |
| Latest Form 4 filing | 2026-07-10 |
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Lorrain Daniel S. | Chief Scientific Officer | S — Open-market sale | 25 | $16.00 | $400 | SEC | |
| Lorrain Daniel S. | Chief Scientific Officer | M — Option exercise | 25 | $1.01 | $25 | SEC | |
| Lorrain Daniel S. | Chief Scientific Officer | M — Option exercise | 1.0K | $1.01 | $1K | SEC | |
| Stengone Carmine N. | CEO and President | S — Open-market sale | 2.5K | $16.00 | $40K | SEC | |
| Lorrain Daniel S. | Chief Scientific Officer | S — Open-market sale | 1.0K | $16.00 | $16K | SEC | |
| Stengone Carmine N. | CEO and President | M — Option exercise | 2.5K | $1.01 | $3K | SEC | |
| Lorrain Daniel S. | Chief Scientific Officer | S — Open-market sale | 2.5K | $16.24 | $41K | SEC | |
| Lorrain Daniel S. | Chief Scientific Officer | M — Option exercise | 4.2K | $1.01 | $4K | SEC | |
| Lorrain Daniel S. | Chief Scientific Officer | S — Open-market sale | 5.9K | $15.67 | $92K | SEC | |
| Stengone Carmine N. | CEO and President | M — Option exercise | 2.5K | $1.26 | $3K | SEC | |
| Stengone Carmine N. | CEO and President | S — Open-market sale | 10.0K | $16.01 | $160K | SEC | |
| Lorrain Daniel S. | Chief Scientific Officer | M — Option exercise | 28.8K | $1.01 | $29K | SEC | |
| Stengone Carmine N. | CEO and President | M — Option exercise | 7.5K | $1.01 | $8K | SEC | |
| Lorrain Daniel S. | Chief Scientific Officer | S — Open-market sale | 28.8K | $16.04 | $462K | SEC | |
| Watkins Tim | CMO & Head of Development | M — Option exercise | 10.8K | $4.50 | $49K | SEC |
All transactions sourced from SEC EDGAR Form 4 filings for Contineum Therapeutics, Inc. (CTNM). Updated in real time as new filings are submitted to the SEC.
| Insider | Form 4 filings | Total transaction value |
|---|---|---|
| Lorrain Daniel S. | 16 | $755K |
| Stengone Carmine N. | 8 | $213K |
| Watkins Tim | 3 | $222K |
| Ignelzi Troy A. | 1 | — |
| Ware Olivia C | 1 | — |
Form 144 must be filed before insiders sell restricted or control stock above SEC thresholds. A cluster of Form 144 notices often precedes a wave of insider distribution.
SEC Form 4 transactions are reported with a one-letter code indicating the type of transaction. Common codes you'll see in CTNM insider filings:
| P | Open-market purchase by the insider |
|---|---|
| S | Open-market sale by the insider |
| A | Grant, award, or other acquisition from the issuer |
| M | Exercise or conversion of derivative security (e.g. options) |
| F | Payment of exercise price or tax liability via share withholding |
| G | Bona-fide gift of securities |
| D | Disposition to the issuer (e.g. share buyback participation) |
| J | Other acquisition or disposition |
| X | Exercise of in-the-money or at-the-money derivative security |
| C | Conversion of derivative security |
| V | Transaction voluntarily reported earlier than required |
Open the live CTNM dashboard on InsiderAlpha for real-time alerts, charting, and full historical filing search.